4-phenylbutyric acid has been researched along with Hyperammonemia in 13 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia has been reported following asparaginase administration, consistent with the mechanisms of asparaginase, which catabolizes asparagine to aspartic acid and ammonia, and secondarily converts glutamine to glutamate and ammonia." | 4.31 | Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia. ( Altintas, B; Eldem, I; Langley, R; Lee, A; Nguyen, H; Shinawi, M; Willis, D, 2023) |
| " Though the treatment was successful in ameliorating hyperammonemia, hyperargininemia persisted." | 3.96 | Sodium phenylbutyrate improved the clinical state in an adult patient with arginase 1 deficiency. ( Fukui, K; Hanai, T; Ishibashi, H; Matsufuji, M; Nakashima, M; Takashima, S; Takeshita, E; Watanabe, Y, 2020) |
| " Her hyperammonemia was corrected by hemodialysis, followed by sodium benzoate, L-arginine, levocarnitine and protein-free diet therapy." | 3.96 | Long-term survival of a patient with acute neonatal-onset metabolic encephalopathy with carbamoyl phosphate synthetase 1 deficiency. ( Ando, Y; Arisaka, O; Imataka, G; Ishii, J; Nitta, A; Takagi, Y; Yoshihara, S, 2020) |
| " Four Phase 1 studies were conducted to characterize the bioavailability (BA) and/or bioequivalence (BE) of ACER-001 (in healthy volunteers) and taste assessment relative to NaPBA powder (in taste panelists)." | 1.91 | Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders. ( Cederbaum, SD; Edwards, J; Kellmeyer, T; Peters, Y; Steiner, RD, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Cederbaum, SD | 1 |
| Edwards, J | 1 |
| Kellmeyer, T | 1 |
| Peters, Y | 1 |
| Steiner, RD | 1 |
| Eriksen, PL | 1 |
| Djernes, L | 1 |
| Vilstrup, H | 1 |
| Ott, P | 1 |
| Lee, A | 1 |
| Eldem, I | 1 |
| Altintas, B | 1 |
| Nguyen, H | 1 |
| Willis, D | 1 |
| Langley, R | 1 |
| Shinawi, M | 1 |
| Mangum, R | 1 |
| Soler-Alfonso, C | 1 |
| Birchansky, S | 1 |
| Stevens, A | 1 |
| Matsufuji, M | 1 |
| Takeshita, E | 1 |
| Nakashima, M | 1 |
| Watanabe, Y | 1 |
| Fukui, K | 1 |
| Hanai, T | 1 |
| Ishibashi, H | 1 |
| Takashima, S | 1 |
| Imataka, G | 1 |
| Ishii, J | 1 |
| Ando, Y | 1 |
| Yoshihara, S | 2 |
| Takagi, Y | 1 |
| Nitta, A | 1 |
| Arisaka, O | 1 |
| Sato, T | 1 |
| Ishii, T | 1 |
| Kato, M | 1 |
| Oyanagi, T | 1 |
| Nakatsuka, S | 1 |
| Kuroda, T | 1 |
| Hasegawa, T | 1 |
| Weiss, N | 1 |
| Tripon, S | 1 |
| Lodey, M | 1 |
| Guiller, E | 1 |
| Junot, H | 1 |
| Monneret, D | 1 |
| Mayaux, J | 1 |
| Brisson, H | 1 |
| Mallet, M | 1 |
| Rudler, M | 1 |
| Imbert-Bismut, F | 1 |
| Thabut, D | 1 |
| Matson, KM | 1 |
| Sonetti, DA | 1 |
| Giva, S | 1 |
| Finnegan, J | 1 |
| Ihidero, P | 1 |
| Maguire, G | 1 |
| Power, B | 1 |
| Knerr, I | 1 |
| Monavari, A | 1 |
| van Straten, G | 1 |
| van Dalen, D | 1 |
| Mesu, SJ | 1 |
| Rothuizen, J | 1 |
| Teske, E | 1 |
| Spee, B | 1 |
| Favier, RP | 1 |
| van Geijlswijk, IM | 1 |
| Bender, HU | 1 |
| Staudigl, M | 1 |
| Schmid, I | 1 |
| Führer, M | 1 |
| Nagamani, SC | 1 |
| Erez, A | 1 |
| Lee, B | 1 |
1 review available for 4-phenylbutyric acid and Hyperammonemia
| Article | Year |
|---|---|
Argininosuccinate lyase deficiency.
Topics: Arginine; Argininosuccinate Lyase; Argininosuccinic Acid; Argininosuccinic Aciduria; Child, Preschoo | 2012 |
2 trials available for 4-phenylbutyric acid and Hyperammonemia
| Article | Year |
|---|---|
Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Liver Cirrhosis; Male; Phenylbut | 2023 |
Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.
Topics: Ammonia; Animals; Bile Acids and Salts; Cross-Over Studies; Dogs; Double-Blind Method; Female; Hyper | 2019 |
10 other studies available for 4-phenylbutyric acid and Hyperammonemia
| Article | Year |
|---|---|
Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Topics: Humans; Hyperammonemia; Nitrogen; Phenylbutyrates; Powders; Rare Diseases; Taste; Urea; Urea Cycle D | 2023 |
Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia.
Topics: Ammonia; Antineoplastic Agents; Asparaginase; Child; Glutamine; Humans; Hyperammonemia; Phenylbutyra | 2023 |
Survival and Neurologic Recovery After Prompt Diagnosis and Aggressive Management of Severe Idiopathic Hyperammonemic Encephalopathy in a Patient with Acute Myeloid Leukemia.
Topics: Adult; Brain Diseases; Female; Humans; Hyperammonemia; Leukemia, Myeloid, Acute; Neurotoxicity Syndr | 2020 |
Sodium phenylbutyrate improved the clinical state in an adult patient with arginase 1 deficiency.
Topics: Adult; Arginase; Arginine; Female; Humans; Hyperammonemia; Hyperargininemia; Phenylbutyrates | 2020 |
Long-term survival of a patient with acute neonatal-onset metabolic encephalopathy with carbamoyl phosphate synthetase 1 deficiency.
Topics: Arginine; Brain Diseases, Metabolic; Carbamoyl-Phosphate Synthase I Deficiency Disease; Carnitine; F | 2020 |
Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: a case report.
Topics: Administration, Oral; Amino Acids, Branched-Chain; Ammonia; Humans; Hyperammonemia; Infant; Male; Ph | 2021 |
Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Topics: Aged; Ammonia; Biomarkers; Case-Control Studies; Female; Hepatic Encephalopathy; Hospital Mortality; | 2018 |
Successful treatment of Ureaplasma-induced hyperammonemia syndrome post-lung transplant.
Topics: Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Graft Rejection; Humans; Hyperammonemia; Immuno | 2019 |
Hyperammonaemia in Neonates and Young Children: Potential Metabolic Causes, Diagnostic Approaches and Clinical Consequences
Topics: Ammonia; Arginine; Biomarkers; Brain Diseases, Metabolic, Inborn; Carnitine; Critical Illness; Diet, | 2019 |
Treatment of Paraneoplastic Hyperammonemia in Fibrolamellar Hepatocellular Carcinoma With Oral Sodium Phenylbutyrate.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Female; Human | 2015 |